The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last few years. Ranging from advanced imaging modalities for detection, new innovative liquid and tissue-based biomarkers, and the recent introduction of PSMA PET imaging have significantly advanced the field, challenging some of the old grounds of truth. The introduction of the Advanced Prostate Cancer Consensus Conference (APCCC) in 2015 represents a milestone in establishing clinical consensus in the care of advanced prostate cancer patients. While the diagnostic part was always an important part of the APCCC series, its growing importance also for earlier stages and detection cannot be adequately addressed in such a format. Accordingly, APCCC's initiators and leading diagnostic experts have agreed to spin out a conference series dedicated to prostate cancer diagnostics: APCCC diagnostics. We invite you to join us to jointly tackle the challenge of APCCC Diagnostics in February 2025 in the beautiful city of Lugano, Switzerland.